Zhonghua Yi Xue Za Zhi. 2023 Sep 12;103(34):2674-2694. doi: 10.3760/cma.j.cn112137-20230630-01114.
Transarterial chemoembolization (TACE) is the most commonly used method in the treatment of unresectable hepatocellular carcinoma (HCC), which is a malignancy of hypervascularity originating from hepatocytes. The experts from Chinese College of Interventionalists (CCI) published Chinese Clinical Practice Guidelines for TACE of HCC in 2018 and updated it in 2021. These guidelines have played an important role in standardizing the clinical practice of TACE treatment for HCC in China. With the updated concept, technological progress, and emergence of high-level evidence in accordance with the principles of evidence-based medicine of TACE for HCC, the guidelines were revised and updated again by the experts from CCI. The 2023 edition guidelines not only adopts a more suitable evidence evaluation and recommendation system, but also adds the following contents: TACE in special circumstances, TACE in multidisciplinary diagnosis and treatment of HCC and the whole process management, TACE quality control, hot spots and development direction of TACE, etc. This guideline is based on the latest evidence-based medical evidence and combined with clinical practice, and aims to standardize TACE treatment of HCC in China.
经动脉化疗栓塞术（TACE）是治疗不可切除肝细胞癌（HCC）最常用的方法，HCC是一种起源于肝细胞的高血供恶性肿瘤。中国介入医师学会（CCI）的专家于2018年发布了《HCC的TACE中国临床实践指南》，并于2021年进行了更新。这些指南在中国规范HCC的TACE治疗临床实践中发挥了重要作用。随着HCC的TACE循证医学原则下更新的概念、技术进步以及高级别证据的出现，CCI的专家再次对指南进行了修订和更新。2023版指南不仅采用了更合适的证据评估和推荐系统，还增加了以下内容：特殊情况下的TACE、HCC多学科诊疗中的TACE及全程管理、TACE质量控制、TACE热点与发展方向等。本指南基于最新的循证医学证据并结合临床实践，旨在规范中国HCC的TACE治疗。
